Show simple item record

Authordc.contributor.authorTroncoso Cotal, Rodrigo 
Authordc.contributor.authorMoraga, Francisco 
Authordc.contributor.authorChiong Lay, Mario 
Authordc.contributor.authorRoldán, Juan 
Authordc.contributor.authorBravo, Roberto 
Authordc.contributor.authorValenzuela, Rodrigo 
Authordc.contributor.authorDíaz Araya, Guillermo 
Authordc.contributor.authorDel Campo, Andrea 
Authordc.contributor.authorSanhueza, Carlos 
Authordc.contributor.authorRodriguez, Andrea 
Authordc.contributor.authorVukasovic, José Luis 
Authordc.contributor.authorMellado, Rosemarie 
Authordc.contributor.authorGreig, Douglas 
Authordc.contributor.authorCastro, Pablo F. 
Authordc.contributor.authorLavandero González, Sergio 
Admission datedc.date.accessioned2019-03-11T12:57:28Z
Available datedc.date.available2019-03-11T12:57:28Z
Publication datedc.date.issued2009
Cita de ítemdc.identifier.citationBasic and Clinical Pharmacology and Toxicology, Volumen 104, Issue 5, 2018, Pages 374-378
Identifierdc.identifier.issn17427835
Identifierdc.identifier.issn17427843
Identifierdc.identifier.other10.1111/j.1742-7843.2008.00370.x
Identifierdc.identifier.urihttp://repositorio.uchile.cl/handle/2250/164741
Abstractdc.description.abstractWe investigated the clinical response of chronic heart failure patients with β2-adrenergic receptor Gln27→Glu polymorphism treated for 6 months with carvedilol, a α/β-antagonist with antioxidant properties. The 6-min. walk test, the left ventricular ejection fraction, heart rate, plasma norepinephrine and malondialdehyde, a stress oxidative marker, concentrations were evaluated at baseline and after treatment for 6 months with carvedilol in 33 stable chronic heart failure patients with the Gln27→Gluβ2-adrenergic receptor polymorphism. Carvedilol significantly increased the left ventricular ejection fraction, while decreasing the heart rate and malondialdehyde plasma concentrations in chronic heart failure patients with the Glu 27β2-adrenergic receptor allele. There were however, no significant changes in patients with the Gln27β2- adrenergic receptor variant. © 2009 Nordic Pharmacological Society.
Lenguagedc.language.isoen
Type of licensedc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
Sourcedc.sourceBasic and Clinical Pharmacology and Toxicology
Keywordsdc.subjectToxicology
Keywordsdc.subjectPharmacology
Títulodc.titleGln27→Gluβ2-adrenergic receptor polymorphism in heart failure patients: Differential clinical and oxidative response to carvedilol
Document typedc.typeArtículo de revista
Catalogueruchile.catalogadorSCOPUS
Indexationuchile.indexArtículo de publicación SCOPUS
uchile.cosechauchile.cosechaSI


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Chile
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Chile